Literature DB >> 318675

Alteration of effectiveness of antibiotics by anaerobiosis.

R M Verklin, G L Mandell.   

Abstract

In vitro antibiotic susceptibility tests of facultative organisms are routinely performed under aerobic conditions, despite the fact that many infections caused by these organisms occur in anaerobic areas, i.e., intra-abdominal absess. Experiments were performed aerobically and anaerobically to determine the susceptibility of E. coli, P. mirabilis, and K. pneumoniae to gentamicin, tobramycin, cephalothin, cefazolin, and cefamandole. Antibiotic sensitivities were determined by disc and agar dilution techniques in air and in anaerobic jars with CO2 absorbed. Tube dilution studies were performed in air and anaerobically and time-kill studies were done in aerobic and anaerobic broth. The amount of aminoglycoside required to inhibit bacterial growth was increased 4 to 20 times by anaerobiosis in 20 of 25 strains tested. Time-kill curves showed that bacterial killing by aminoglycosides was markedly impaired by anaerobiosis. Anaerobic conditions had no effect on the rate or extent of killing by cephalosporins. These data may have significance in determination of antibiotic susceptibility of facultative organisms under anaerobic tissue conditions. Antibiotic sensitivity testing done on these organisms in air may not reflect the actual state of antibiotic-bacterial interaction under conditions of the infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318675

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  25 in total

1.  Value of hyperbaric oxygen in bacterial and fungal malignant external otitis treatment.

Authors:  Waldemar Narozny; Jerzy Kuczkowski; Czeslaw Stankiewicz; Jacek Kot; Boguslaw Mikaszewski; Tomasz Przewozny
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-04-22       Impact factor: 2.503

2.  Adjunctive therapies in the treatment of osteomyelitis.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

3.  [Effects of hyperbaric oxygen therapy (HBO) during treatment of infected free bone transplants. A Case report].

Authors:  S Lentrodt; J Lentrodt
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

Review 4.  Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

5.  Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm.

Authors:  P S Stewart; W Wattanakaroon; L Goodrum; S M Fortun; B R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Hyperoxia and the antimicrobial susceptibility of Escherichia coli and Pseudomonas aeruginosa.

Authors:  K H Muhvich; M K Park; R A Myers; L Marzella
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Prevention of acute and chronic ascending pyelonephritis in rats by aminoglycoside antibiotics accumulated and persistent in kidneys.

Authors:  J Bille; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Current management of upper respiratory tract and head and neck infections.

Authors:  Itzhak Brook
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-05       Impact factor: 2.503

10.  Influence of inflammation on the efficacy of antibiotic treatment of experimental pyelonephritis.

Authors:  P R Meylan; G Braoudakis; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.